扶正抗癌方联合TACE、3-DCRT治疗原发性肝癌的疗效观察

Clinical Efficacy of Fuzheng Kang'ai Prescription(扶正抗癌方) Combined with TACE and 3-DCRT in the Treatment of Primary Liver Cancer

目的:观察扶正抗癌方联合肝动脉化疗栓塞术(TACE)、三维适形放疗(3-DCRT)治疗原发性肝癌的疗效。方法:将50例原发性肝癌患者随机分为两组各25例,治疗组患者予以扶正抗癌方联合TACE、3-DCRT治疗,对照组患者予TACE、3-DCRT治疗,治疗前和治疗结束后4周分别评估患者实体瘤大小、生活质量评分标准Karnofsky评分、细胞免疫功能、毒副反应及生存率。结果:治疗组有效率为56.00%(14/25),对照组有效率为40.00%(10/25),两组有效率比较,差异无统计学意义(P>0.05)。治疗结束后4周,治疗组患者Karnofsky评分高于治疗前(P<0.05),且治疗结束后4周,治疗组患者Karnofsky评分高于对照组,差异有统计学意义(P<0.05)。治疗结束后4周,治疗组患者CD3^(+)CD4^(+)、CD3^(+)CD8^(+)、CD3^(+)CD4^(+)/CD3^(+)CD8^(+)均高于对照组,差异均有统计学意义(P<0.05)。治疗组恶心呕吐、腹痛发生率低于对照组,差异有统计学意义(P<0.05)。治疗组0.5年、1年生存率分别为100.00%(25/25)、88.00%(22/25),对照组0.5年、1年生存率分别为92.00%(23/25)、76.00%(19/25),两组0.5、1年生存率比较,差异均无统计学意义(P>0.05)。结论:扶正抗癌方联合TACE、3-DCRT治疗原发性肝癌,可有效提高其生活质量,改善机体免疫力,减少不良反应的发生。

Objective:To observe the effect of Fuzheng Kang’ai Prescription combined with transcathet er arterial chemoembolization(TACE)and three dimensional conformal radiotherapy(3-DCRT)on primary liver cancer.Methods:Totally 50 patients with primary liver cancer were randomly divided into two groups,25 cases in each group.Patients were treated with Fuzheng Kang’ai Prescription combined with TACE and 3-DCRT in treatment group,and TACE and 3-DCRT in control group.The size of solid tumors,the Karnofsky score for quality of life score,cellular immune function,toxic and side effects and survival rate were evaluated respectively,before treatment and four weeks after treatment.Results:The effective rate was 56.00%(14/25)in treatment group and 40.00%(10/25)in control group.There was no significant difference in the effective rate between the two groups(P>0.05).After four weeks of treatment,the Karnofsky scores of patients in the treatment group was higher than that before treatment(P<0.05),and the treatment group showed higher Karnofsky scores than control group(P<0.05).After four weeks of treatment,the treatment group showed higher CD3^(+)CD4^(+),CD3^(+)CD8^(+) and CD3^(+)CD4^(+)/CD3^(+)CD8^(+) than control group,and the differences were statistically significant(P<0.05).The treatment group showed lower incidence of nausea,vomiting and abdominal pain than control group,and the difference was statisticallysignificant(P<0.05).The 0.5-year survival rates and 1-year survival rates were respectively 100.00%(25/25) and 88.00%(22/25) in treatment group,and respectively 92.00%(23/25) and 76.00%(19/25) in control group.There was no statistically significant difference in 0.5-year survival rates and 1-year survival rates between the two groups(P>0.05).Conclusion:Fuzheng Kang’ai Prescription combined with TACE and 3-DCRT can effectively improve the quality of life of patients with primary liver cancer,improve the immunity and reduce the occurrence of adverse reactions.